Ginger Graham, CEO of Amylin Pharmaceuticals, joined the company with the expectation of making the signature of drug, Symlin, to market. However, unforeseen regulatory issues put the approval process is in danger. At the same time, the company has a second drug, Byetta, in its pipeline. Graham must decide how to manage the limited resources of the company at the same time completing the deal, which has a huge potential for the future. Graham knows that Amylin immediate success depends on its ability to commercialize its products, but the long-term success depends on the completion of their pipelines. Can the company do this successfully? "Hide
by Richard G. Hamermesh, Rachel Gordon Source: Harvard Business School 19 pages. Publication Date: December 9, 2008. Prod. #: 809011-PDF-ENG
Related Case Solutions & Analyses:
Intel Commercials Video
Lycos (A): The Tripod Decision
Major Global Stock Exchanges
Fresh Look at Industry and Market Analysis
Taran Swan at Nickelodeon Latin America (D)
Double Dealmaking in the Browser Wars (A)
CommonAngels (TM) (B)
Center for Integration of Medicine and Innovative Technology (CIMIT), Spanish Version
BUSINESS PLAN-TRUCKING BUSINESS
B and F Computer Repair
